Search
Thyroid, porcine
go.drugbank.com/drugs/DB09100ApprovedInvestigational[A190831] Thyroid extract is no longer considered a first line therapy as it delivers a dose that is inconsistent with the stated strength of the tablet. … [A190813] Thyroid extracts were never FDA approved as their use in the United States predates the FDA.[A190831]
TAK-428
go.drugbank.com/drugs/DB05499ExperimentalIt is based on the novel concept that peripheral nervous tissue that was damaged by diabetes can be repaired and regenerated by stimulating an increase in neurotrophic factors. … TAK-428 is a drug for treating diabetic neuropathy.
Oliceridine
go.drugbank.com/drugs/DB14881ApprovedInvestigational[A218041, A218046] Opioid receptors are seven-transmembrane G-protein-coupled receptors (GPCRs), of which the μ-opioid receptor subtype is predominantly targeted by and is responsible for the effects of … [A218026, A218031, A218036, A218041, A218046] Oliceridine (formerly known as TRV130) is a "biased agonist" at the μ-opioid receptor by preferentially activating the G-protein pathway with minimal receptor
Flutamide
go.drugbank.com/drugs/DB00499ApprovedInvestigationalAn antiandrogen with about the same potency as cyproterone in rodent and canine species.
Categories: Androgen Receptor Antagonists, Androgen Receptor InhibitorsGinsenoside Rb1
go.drugbank.com/drugs/DB06749ExperimentalNutraceuticalRecent research shows that Rb1 affects rat embryo development and has teratogenic effects, causing birth defects. … Rb1 appears to be most abundant in Panax quinquefolius (American Ginseng). Rb1 seems to affect the reproductive system in animal testicles.
Ansuvimab
go.drugbank.com/drugs/DB16385ApprovedInfection with pathogenic filoviruses, such as _Zaire ebolavirus_ (Ebola virus, EBOV), can cause severe hemorrhagic fever in humans, resulting in frequent outbreaks with case fatality rates as high as … conserved region of the GP<sub>1,2</sub> protein that is responsible for interacting with the host NPC1 protein to mediate EBOV endolysosomal escape, a key step in the EBOV lifecycle.
Eniluracil
go.drugbank.com/drugs/DB03516Investigationals most widely-used oncology agents. 5-FU is widely used in the U.S. and is often first or second line therapy for a variety of cancers including colorectal, breast, gastric, head and neck, ovarian and … Eniluracil could improve 5-FU by increasing its effectiveness, reducing its side effects and/or making it orally available.
Icotinib
go.drugbank.com/drugs/DB11737Investigational. was given a “May Proceed” from the US FDA to conduct a Phase I study for the evaluation of icotinib as a treatment of EGFR+ Non-Small Cell Lung Cancer (NSCLC). … Icotinib is a potent and specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) Icotinib was approved in China by the SFDA in June, 2011 and in January 2014, Beta Pharma, Inc
Categories: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitorsRipretinib
go.drugbank.com/drugs/DB14840ApprovedInvestigational[L13769] It is the first drug approved as a fourth-line therapy in the specific setting of prior treatment with a minimum of 3 other kinase inhibitors.[L13778] … Ripretinib, also known as Qinlock, is manufactured by Deciphera Pharmaceuticals and was initially approved by the FDA on May 15, 2020.
Categories: Stem Cell Factor (KIT) Receptor Inhibitors, Platelet-derived Growth Factor alpha Receptor InhibitorsTiclopidine
go.drugbank.com/drugs/DB00208ApprovedIt is a prodrug that is metabolised to an active form, which blocks the ADP receptor that is involved in GPIIb/IIIa receptor activation leading to platelet aggregation. … Ticlopidine is an effective inhibitor of platelet aggregation.
Categories: Purinergic P2 Receptor Antagonists, Purinergic P2Y Receptor Antagonists